Management of recurrent vulvovaginal candidiasis: Unresolved issues

Current Infectious Disease Reports

Volumn 8, Issue 6, 2006, Pages 481-486

  Sobel, Jack D ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BORIC ACID; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PYRROLE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; COLONY FORMING UNIT; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; HOST SUSCEPTIBILITY; HUMAN; INFECTION PREVENTION; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; POLYMERASE CHAIN REACTION; RECURRENT INFECTION; REINFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; VAGINA CANDIDIASIS;

EID: 33750852015     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0023-7     Document Type: Review

References (22)

1. Foxman B: The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Healtb 1990, 80:329-331.
2. Sobel JD: Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985, 152(7 Pt 2):924-935.
3. Sobel JD: Pathogenesis of recurrent vulvovaginal candidiasis. Curr Infect Dis Rep 2002, 4:514-519.
4. Babula O, Lazdane G, Kroica J, et al.: Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005, 40:1258-1262.
5. Fidel PL Jr: History and new insights into host defense against vaginal candidiasis. Trends Microbiol 2004, 12:220-227.
6. Sobel JD: Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986, 315:1455-1458.
7. Sobel JD, Wiesenfeld HC, Martens M, et al.: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004, 351:876-883.
8. Davidson F, Mould RF: Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment. Br J Vener Dis 1978, 54:176-183.
9. Houang ET, Chappatte O, Byrne D, et al.: Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 1990, 34:909-910.
10. Moosa MY, Sobel JD, Elhalis H, et al.: Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium. Antimicrob Agents Chemother 2004, 48:161-167.
11. Sobel JD, Zervos M, Reed BD, et al.: Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003, 47:34-38.
12. Rigg D, Miller MM, Metzger WJ: Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990, 162:332-336.
13. Rosedale N, Browne K: Hyposensitisation in the management of recurring vaginal candidiasis. Ann Allergy 1979, 43:250-253.
14. Sobel JD, Vazquez JA: Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996, 22:726-727.
15. Mathema B, Cross E, Dun E, et al.: Prevalence of vaginal colonization by drug-resistant Candida species in collegeage women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001, 33:E23-27.
16. Vazquez JA, Peng G, Sobel JD, et al.: Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis 2001, 33:1069-1075.
17. Sobel JD, Ohmit SE, Schuman P, et al.: The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001, 183:286-293.
18. Nyirjesy P, Alexander AB, Weitz MV: Vaginal Candida parapsilosis: pathogen or bystander? Infect Dis Obstet Gynecol 2005, 13:37-41.
19. Singh S, Sobel JD, Bhargava P, et al.: Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002, 35:1066-1070.
20. Sobel JD, Chaim W, Nagappan V, Leaman D: Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003, 189:1297-1300.
21. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG: Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 1984, 86:503-513.
22. Sobel JD, Kapernick PS, Zervos M, et al.: Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001, 185:363-369.